Inequities in the Presentation of Disease and the Start of Treatment for De Novo Metastatic Breast Cancer - Top-Institutions - MDSpire

Inequities in the Presentation of Disease and the Start of Treatment for De Novo Metastatic Breast Cancer

  • By

  • Jincong Q. Freeman

  • Apoorva Ravichandran

  • Sarah Poland

  • Maeve A. Hennessy

  • Wenji Guo

  • Rita Nanda

  • April 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Breast Cancer Research
    • Health Disparities

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Breast Cancer
    • Cancer Epidemiology

  • #3

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Breast Cancer
    • Health Equity

  • #4

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Breast Cancer
    • Disparities Research

  • #5

    University of Chicago Medicine Comprehensive Cancer Center
    University of Chicago Medicine Comprehensive Cancer Center

    Chicago, IL

    Key Differentiators

    • Oncology
    • Breast Cancer
    • Health Disparities

Original Source(s)

Inequities in the Presentation of Disease and the Start of Treatment for De Novo Metastatic Breast Cancer

  • by Jincong Q. Freeman, Apoorva Ravichandran, Sarah Poland, Maeve A. Hennessy, Wenji Guo, Rita Nanda

  • April 23, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Potential targets for boron transport in boron neutron capture therapy

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma